The remarkable success of EGFR‐TKIs for the treatment of lung adenocarcinoma patients with advanced‐mutated EGFR has been undermined by the invariable development of acquired resistance to these drugs. The gene discussed is EGFR; the disease is lung adenocarcinoma.